

Nitin Damle, Ph.D.
Vice President, Biology
Sun Pharma Research Division
India

Title: Antibody-Drug Conjugates: Challenges in Translating Preclinical Success into Clinical Reality in Cancer Therapy Immunotherapy

Abstract:

Antibody-drug conjugates represent a clinically validated therapeutic strategy in cancer therapy. A large number of ADC candidates targeted to a diverse array of tumor-associated antigens have been created and many of these have shown exciting antitumor efficacy in preclinical studies. However, the number of regulatory approved ADCs are only handful, unlike >50 therapeutic monoclonal antibodies currently used in cancer therapy. While the reasons underlying the lack of wider success for ADCs can be numerous, some common denominators impacting the success of ADC therapeutics in the clinic will be discussed. As newer technologies emerge allowing creation of ADCs with improved biophysical and biochemical attributes of ADCs, we may be getting closer to seeing ADCs that are broadly applicable against solid tumors.